Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing

Firm ‘Utterly Disagrees’ With CMA And Vows To Appeal Decision

Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.

The CMA announced fines of more than £100m over liothyronine pricing • Source: Almy

More from United Kingdom

More from Europe